Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
04/2003
04/01/2003US6541426 Melt emulsification; controlling particle size
04/01/2003US6541163 Process of powder for bath from natural plants
04/01/2003US6541049 Method for production of arachidonic acid
04/01/2003US6541048 Coated chewing gum products containing an acid blocker and process of preparing
04/01/2003US6541042 Comprising 5-25% by weight terpinen-4-ol-containing essential oils and 0.01-10% by weight tannin-containing medicinal plants or extracts thereof, used for topical treatment of cutaneous and mucous membrane affections in veterinary sector
04/01/2003US6541039 For use in tumor therapy by hyperthermia
04/01/2003US6541037 Delivery vehicle
04/01/2003US6541035 Nanosheres comprising a biocompatible polysaccharide
04/01/2003US6541034 Matrix material containing sugars and/or sugar alcohols and process for its preparation
04/01/2003US6541033 Thermosensitive biodegradable hydrogels for sustained delivery of leptin
04/01/2003US6541031 Composition with release-controlling action
04/01/2003US6541030 Subjectign aqueous mixture of a water insoluble core material, a water soluble glucopyranosidyl material, and an emulsifying formulation to a pressure force to form an aqueous micro-emulsion, and removing water to form microcapsules
04/01/2003US6541029 Nutrient infusion preparation
04/01/2003US6541025 Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
04/01/2003US6541021 Completely implanting in a patient, at a implntation site, a controlled release drug delivery device containing a pump and a drug selected from fentanyl and a fetanyl congener, such as sufentanil for treating the pain for atleast about 3-days
04/01/2003US6541020 An antiviral agent consists of a polymer material that forms a hydrogel at physiological temperatures, and a polypeptide having a specific amino acid sequence
04/01/2003US6541018 Nanoemulsion based on glycerol fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields
04/01/2003US6541016 Monoalkyl phosphoric esters, dialkyl phosphoric esters, and, in small amounts, trialkyl phosphoric esters or salts, based on beta-branched fatty alcohols, effective in lowering the surface tension of both polar and nonpolar liquids
04/01/2003US6541015 Water soluble prodrug with a biologically active agent link trapped in a hydrogel and controllably released by diffusion
04/01/2003US6541014 Three dosages forms having different release profile, extending dosage to twelve hours
04/01/2003US6541001 A stable compacted, compressed or hard tableted vaccine formulation containing a freeze dried antigenic component and a dissolution aid
04/01/2003US6541000 Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
04/01/2003US6540993 Method of treating inflammatory bowel disease using a topical formulation of IL-11
04/01/2003US6540990 Topical application to the eye of an acetylcholine esterase inhibitor, such as a mercaptoethyltrimethylammonium salt, to improve visual acuity
04/01/2003US6540984 Aqueous dispersions of crystalline polymers and uses
04/01/2003US6540983 A drug selected from an insulin analog, and/or amylin, a fluid propellant carrier, and a stabilizer comprising water added in addition to nascent formulation water; treating diabetes; inhalers
04/01/2003US6540982 Medical aerosol formulation
04/01/2003US6540717 Implantable vascular access device
04/01/2003US6540715 Method and device for in-situ formulation of a medicinal solution for parenteral application
04/01/2003US6540393 Apparatus for preparing microparticles using in-line solvent extraction
04/01/2003CA2405918A1 Controlled release macrolide pharmaceutical formulations
04/01/2003CA2317785C Liniment for topical application
04/01/2003CA2270975C Stabilized sustained release tramadol formulations
04/01/2003CA2222309C Composition for treating keratinous material, including at least one silicone-grafted polymer and at least one thickening polymer or copolymer of (meth)acrylamide or a (meth)acrylamide derivative, and uses thereof
04/01/2003CA2163539C N-morpholino-n-nitrosaminoacetonitrile cyclodextrin inclusion complexes
04/01/2003CA2044676C Pharmaceutical composition for rectal administration of active principles exhibiting a prevalently topical medication action at the colon level
03/2003
03/28/2003CA2357982A1 Solid compositions comprising ramipril
03/27/2003WO2003025155A1 Fermentation product of cyptoporus volvatus and its preparation method and use
03/27/2003WO2003025062A1 Polymeric hydrogel
03/27/2003WO2003024952A1 Bioprecursors for percutaneous application
03/27/2003WO2003024583A1 Novel calixarene based dispersible colloidal systems in the form of nanoparticles
03/27/2003WO2003024528A1 Systematical administration of some oxazolidinones, e.g. linezolid, for the treatment for ocular infections
03/27/2003WO2003024503A2 Device and method for accurate delivery of an active agent
03/27/2003WO2003024495A1 Microtubes for therapeutic delivery
03/27/2003WO2003024475A1 Water-insoluble sustained release compositions, preparations thereof and process for producing the same
03/27/2003WO2003024455A2 Stent coated with a sustained-release drug delivery and method for use thereof
03/27/2003WO2003024452A1 Novel medicaments for inhalation
03/27/2003WO2003024438A1 Composition comprising cysteamine for improving lactation in dairy animals
03/27/2003WO2003024435A1 Immune modulation with polystyrene sulfonate
03/27/2003WO2003024433A2 Compositions for treatment of common cold, comprising ipratropium and xylometazoline
03/27/2003WO2003024432A2 Device for transdermal administration for the treatment of urinary tract disorders
03/27/2003WO2003024431A1 Device for the administration of an active agent to the human skin
03/27/2003WO2003024430A1 Morphine polymer release system
03/27/2003WO2003024429A1 Polymer release system
03/27/2003WO2003024428A1 Amino acid modulated extended release dosage form
03/27/2003WO2003024427A1 Tableted oral extended release dosage form
03/27/2003WO2003024426A1 Controlled release solid dispersions
03/27/2003WO2003024425A1 Nanoparticulate insulin formulations
03/27/2003WO2003024424A1 Stabilization of active agents by formulation into nanoparticulate form
03/27/2003WO2003024423A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment
03/27/2003WO2003024422A1 Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities
03/27/2003WO2003024421A2 Triclosan dosage form
03/27/2003WO2003024420A1 Ophthalmic depot formulations for periocular or subconjunctival administration
03/27/2003WO2003024406A2 Nestin-expressing hair follicle stem cells
03/27/2003WO2003024396A2 Dry powder medicament formulations
03/27/2003WO2003024383A2 Methods and apparatus for improved administration of analgesics
03/27/2003WO2003024360A1 Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
03/27/2003WO2003024357A2 Microfabricated nanopore device for sustained release of therapeutic agent
03/27/2003WO2003024355A1 Intraruminal device
03/27/2003WO2003024297A2 Cell storage and delivery system
03/27/2003WO2003024240A1 Pet food product and method of manufacture
03/27/2003WO2003024223A1 Pesticidal formulations
03/27/2003WO2003002149A3 Use of pigment such as e.g. titanium dioxide for obtaining a special optical effect on oral medicament or food
03/27/2003WO2003000237A3 Biodegradable polymer coompositions
03/27/2003WO2002102311A3 Nanoparticles for treating targeted tissues and cells
03/27/2003WO2002099457A3 Microchip devices with improved reservoir opening
03/27/2003WO2002096347A3 Metering and packaging of controlled release medication
03/27/2003WO2002094254A3 Abuse resistant pharmaceutical composition containing capsaicin
03/27/2003WO2002092054A3 Immune modulation device for use in animals
03/27/2003WO2002074332A3 Method to enhance the immunogenicity of an antigen
03/27/2003WO2002062393A3 Coating for orally administered compositions
03/27/2003WO2002062319A3 Microsphere delivery of mucin peptides
03/27/2003WO2002056829A3 Methods for preparing purified daptomycin
03/27/2003WO2002054868A3 Pulmonary delivery of polyene antifungal agents
03/27/2003WO2002053190A3 Particles for inhalation having sustained release properties
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002053089A3 Stable skin conditioning compositions containing retinoid boosters
03/27/2003WO2002049552A3 Solution for removing cataracts via liquefracture
03/27/2003WO2002043706A3 Prolamin-based sustained-release compositions and delayed-onset compositions
03/27/2003WO2002038170A3 Stabilized inteferon compositions
03/27/2003WO2002032413A3 A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes
03/27/2003WO2002026212A3 Microparticle compositions and methods for the manufacture thereof
03/27/2003WO2002019999A3 Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
03/27/2003WO2002007767A3 Pharmaceutical suspension compositions lacking a polymeric suspending agent
03/27/2003WO2001097865A3 Multiple phase cross-linked compositions and uses thereof
03/27/2003US20030060559 Thermally reversible water in oil in water emulsions
03/27/2003US20030060506 Bile secretion promoting composition
03/27/2003US20030060493 Kit comprising a pharmaceutical composition containing repinotan or a physiologically acceptable salt of repinotan, and a means for the determination of the concentration of repinotan or its metabolites in body
03/27/2003US20030060486 Liquid formulations for the prevention and treatment of mucosal diseases and disorders
03/27/2003US20030060483 Method of increasing pharmaceutical market
1 ... 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 ... 2991